Glycomet-GP 1 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. This dual mechanism addresses hyperglycemia through complementary pathways, making Glycomet-GP 1 Forte effective in achieving glycemic control in patients inadequately controlled by diet and exercise alone. The prolonged-release formulation ensures a steady release of active ingredients, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. Glycomet-GP 1 Forte is indicated for adult patients with type 2 diabetes who require combination therapy for optimal blood sugar regulation. It should be used alongside lifestyle modifications, including diet and exercise. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Contraindications include diabetic ketoacidosis, severe renal dysfunction, and hypersensitivity to components. Proper adherence to prescribed dosage and medical supervision is essential to maximize therapeutic benefits and reduce adverse effects.